Clover Biopharmaceuticals, Ltd. (SEHK: 2197)
Health Care · Biotechnology · CN
HK$2.37
-1.25% today · +203.8% 1Y
Clover Biopharmaceuticals, Ltd. (SEHK: 2197) operates in the Biotechnology industry within the Health Care sector. The company is valued at $392.02M and employs 257 people.
Over the last twelve months the share price has gained 203.8%, trading between 0.63 and 3.20.
Tweenvest scores Clover Biopharmaceuticals, Ltd. across four factors: quality 19/100, value 69/100. Its strongest factor is value.
2197 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $392.02M
- Revenue (TTM)
- $501.12K
- P/E
- —
- EPS
- -0.16
- Dividend yield
- —
- Beta (5Y)
- 2.57
- 52-week high
- HK$3.20
- 52-week low
- HK$0.63
- Avg volume (3M)
- —
- Shares outstanding
- 1.30B
- Employees
- 257
- Next earnings
- —
About Clover Biopharmaceuticals, Ltd.
Clover Biopharmaceuticals, Ltd. is a biotechnology enterprise focused on discovering, developing, and commercializing innovative vaccines and biological therapies. Their efforts target infectious diseases, various cancers, and autoimmune conditions. The company's pipeline features several key candidates: SCB-2019 (CpG 1018/Alum): A COVID-19 vaccine candidate currently advancing through Phase II/III clinical trials. SCB-313: A trimeric fusion protein aimed at treating severe intracavitary malignancies, including malignant ascites, malignant pleural effusions, and peritoneal carcinomatosis, addressing a significant global medical need. SCB-808: Undergoing pivotal Phase III clinical trials for the management of rheumatic disorders. SCB-420: An aflibercept biosimilar in preclinical development for ophthalmologic conditions like wet age-related macular degeneration. SCB-219: A novel TPOR agonist in preclinical stages for the treatment of chemotherapy-induced thrombocytopenia and immune thrombocytopenic purpura. Clover also holds a collaboration and supply agreement with Dynavax, which provides its CpG 1018 adjuvant for use in preclinical studies. The company was established in 2007 and is based in Shanghai, China.
- ISIN
- KYG2280A1076
- Founded
- 2007
- Listed since
- Nov 5, 2021
- Exchange
- The Stock Exchange of Hong Kong Ltd.
- Currency
- HKD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $467.44B | $264.52 | -0.17% |
| Amgen Inc.NasdaqGS: AMGN | $239.95B | $445.03 | +0.27% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.95B | $146.74 | +0.42% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.79B | $547.59 | -0.08% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $82.73B | $828.50 | -0.66% |
| argenx SEENXTBR: ARGX | $63.06B | €874.40 | +1.18% |
| CSL LimitedASX: CSL | $57.94B | AU$169.11 | +0.48% |
| Moderna, Inc.NasdaqGS: MRNA | $55.45B | $142.34 | +2.48% |
Figures last refreshed Aug 18, 2026.